| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,462 | -9,958 |
| Depreciation and amortization expense | 7,190 | 4,814 |
| Inventory write-offs | 0 | - |
| Amortization of financing lease right-of-use asset | 153 | 102 |
| Accretion of interest on securities | 727 | 491 |
| Non-cash lease expense | 974 | 582 |
| Gain on lease termination/modification | 450 | 450 |
| Net realized loss on investments | 0 | 0 |
| Stock-based compensation | 3,608 | 2,667 |
| Change in fair value of contingent consideration | 0 | 0 |
| Change in fair value of convertible debentures, convertible notes payable and option liability | 5,312 | 5,250 |
| Loss on issuance of convertible debentures | 0 | 0 |
| Gain on high trail extinguishment | 0 | 0 |
| Disposal of internal-use software | 0 | - |
| Intangible assets and other long-lived assets impairment | 0 | 0 |
| Loss on rou asset impairment | 0 | - |
| Disposal of property and equipment | -258 | -258 |
| Cost of leased equipment sold to customer | 348 | 215 |
| Accounts receivable | -226 | -1,257 |
| Inventory | -3,342 | -1,834 |
| Prepaid expenses and other current assets | 2,235 | -45 |
| Other assets | -992 | -666 |
| Accounts payable | -973 | -719 |
| Accrued expenses, contract liabilities, and lease liabilities, net | -1,102 | -1,823 |
| Net cash used in operating activities | -12,170 | -6,251 |
| Purchases of property and equipment | 0 | 0 |
| Purchase of available for sale securities | 177,527 | 116,642 |
| Sale and maturity of available for sale securities | 160,771 | 104,555 |
| Net cash (used in)/provided by investing activities | -16,756 | -12,087 |
| Principal payments on financing lease liability | 53 | 34 |
| Proceeds from sale of common stock and warrants | 29,347 | 16,408 |
| Offering costs on sale of common stock and warrants | 1,992 | 1,023 |
| Proceeds from sale of common stock under employee stock purchase plan | 0 | 0 |
| Proceeds from warrant exercises | 9 | 9 |
| Proceeds from issuance of convertible debentures | 0 | 0 |
| Payments on high trail notes | 0 | 0 |
| Payments on convertible debentures | 4,875 | 3,000 |
| Debt issuance costs on sale of convertible debentures | 0 | 0 |
| Payments of retirement fees for redemption of high trail notes | 0 | - |
| Net cash provided by/(used in) financing activities | 22,436 | 12,360 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -18 | -33 |
| Net decrease in cash, cash equivalents and restricted cash | -6,508 | -6,011 |
| Cash and cash equivalents at beginning of period | 9,573 | - |
| Cash and cash equivalents at end of period | 3,065 | - |
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)